Last edition
News about "Hansa Biopharma AB"
Hansa Biopharma's Imlifidase BLA Accepted by US FDA for Priority Review
FDA accepts Hansa Biopharma’s BLA for imlifidase, supported by strong Phase III ConfIdeS data demonstrating significant kidney function improvement in highly sensitized transplant patients.
Hansa Biopharma AB | 20/02/2026 | By News Bureau | 257
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members